Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.
Neri S, Bertino G, Petralia A, Giancarlo C, Rizzotto A, Calvagno GS, Mauceri B, Abate G, Boemi P, Di Pino A, Ignaccolo L, Vadalà G, Misseri M, Maiorca D, Mastrosimone G, Judica A, Palermo F. Neri S, et al. Among authors: bertino g. J Clin Gastroenterol. 2010 Oct;44(9):e210-7. doi: 10.1097/MCG.0b013e3181d88af5. J Clin Gastroenterol. 2010. PMID: 20838237 Clinical Trial.
The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin.
Malaguarnera M, Vacante M, Bertino G, Neri S, Malaguarnera M, Gargante MP, Motta M, Lupo L, Chisari G, Bruno CM, Pennisi G, Bella R. Malaguarnera M, et al. Among authors: bertino g. J Interferon Cytokine Res. 2011 Sep;31(9):653-9. doi: 10.1089/jir.2011.0010. J Interferon Cytokine Res. 2011. PMID: 21923249 Clinical Trial.
L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin.
Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Li Volti G, Galvano F. Malaguarnera M, et al. Among authors: bertino g. World J Gastroenterol. 2011 Oct 21;17(39):4414-20. doi: 10.3748/wjg.v17.i39.4414. World J Gastroenterol. 2011. PMID: 22110268 Free PMC article. Clinical Trial.
Rare benign tumors of the liver: still rare?
Bertino G, Ardiri A, Demma S, GiuseppeCalvagno S, Toro A, Basile E, Campagna D, Ferraro G, Frazzetto E, Proiti M, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M, Amaradio MD, Pricoco G, Di Carlo I. Bertino G, et al. Among authors: bertino n. J Gastrointest Cancer. 2014 Jun;45(2):202-17. doi: 10.1007/s12029-014-9580-4. J Gastrointest Cancer. 2014. PMID: 24510731 Free PMC article. Review.
Chronic hepatitis C: This and the new era of treatment.
Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri MI, Scuderi L, Malaguarnera G, Bertino N, Rapisarda V, Di Carlo I, Toro A, Salomone F, Malaguarnera M, Bertino E, Malaguarnera M. Bertino G, et al. Among authors: bertino e, bertino n. World J Hepatol. 2016 Jan 18;8(2):92-106. doi: 10.4254/wjh.v8.i2.92. World J Hepatol. 2016. PMID: 26807205 Free PMC article. Review.
Hepatocellular carcinoma and the risk of occupational exposure.
Rapisarda V, Loreto C, Malaguarnera M, Ardiri A, Proiti M, Rigano G, Frazzetto E, Ruggeri MI, Malaguarnera G, Bertino N, Malaguarnera M, Catania VE, Di Carlo I, Toro A, Bertino E, Mangano D, Bertino G. Rapisarda V, et al. Among authors: bertino g, bertino e, bertino n. World J Hepatol. 2016 May 8;8(13):573-90. doi: 10.4254/wjh.v8.i13.573. World J Hepatol. 2016. PMID: 27168870 Free PMC article. Review.
208 results